What is DRTS's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.14B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for DRTS?

P/E (TTM) is n/a and 52-week range is $3.43 to $15.79 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s DRTS figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for DRTS?

The company profile lists net income (TTM) near $-60M, EPS (TTM) near $-0.66 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Alpha Tau Medical Ltd based, and what identifiers does Chartloom list?

The company context section lists headquarters in Jerusalem, IL, 90.3M shares outstanding, ISIN IL0011839383 when available from company profile and filing metadata.

Free AI scores & summaries library

Alpha Tau Medical Ltd

$DRTS

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

$12.61

+2.60%

Free AI scores & summaries library

Alpha Tau Medical Ltd

$DRTS

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

$12.61

+2.60%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. Company's technology relies on the diffusion of atoms that emit alpha particles within the tumor tissue, and enables alpha radiation to reach the the entire tumor. Precise amounts of radioactive radium-224 affixed that emit short-range alpha radiation enables to damages and kills cancer cells within a short period of time. The firm has one subsidiary Healthcare Capital Corp.

Employees

121

Website

www.alphatau.com/

IPO

2022-03-08

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (TTM)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

IL0011839383

Headquarters

Jerusalem, IL

Shares outstanding

90.3M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

8.99%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. Company's technology relies on the diffusion of atoms that emit alpha particles within the tumor tissue, and enables alpha radiation to reach the the entire tumor. Precise amounts of radioactive radium-224 affixed that emit short-range alpha radiation enables to damages and kills cancer cells within a short period of time. The firm has one subsidiary Healthcare Capital Corp.

Employees

121

Website

www.alphatau.com/

IPO

2022-03-08

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)